KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Retained Earnings (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Retained Earnings data on record, last reported at -$2.7 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 638797.16% year-over-year to -$2.7 billion; the TTM value through Dec 2025 reached -$2.7 billion, down 638797.16%, while the annual FY2025 figure was -$2.7 billion, 638797.16% down from the prior year.
  • Retained Earnings reached -$2.7 billion in Q4 2025 per PACB's latest filing, down from $415000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $422000.0 in Q4 2024 and bottomed at -$2.7 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$928.8 million, with a median of -$577.1 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 1756304.05% in 2022, then skyrocketed 100.02% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$1.1 million in 2021, then tumbled by 338.36% to -$4.8 million in 2022, then plummeted by 38495.49% to -$1.8 billion in 2023, then surged by 100.02% to $422000.0 in 2024, then plummeted by 638797.16% to -$2.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$2.7 billion in Q4 2025, $415000.0 in Q3 2025, and -$2.6 billion in Q2 2025.